

Top 10 Clinical Conditions by Cost

Episode Treatment Group	Members	Total Cost	Cost per Member	Benchmark Cost/Mbr	Member Rate per 1000	
					Boston	Benchmark
1 Joint Degeneration, Localized	938	\$5,479,578	\$5,842	\$3,556	221.1 [s]	182.3
2 Coronary Artery Disease	407	\$3,136,064	\$7,705	\$7,562	95.9 [s]	68.5
3 Hypertension	1,928	\$2,423,926	\$1,257	\$816	454.5 [s]	356.3
4 Depression	682	\$2,269,298	\$3,327	\$1,979	160.8 [s]	104.9
5 Diabetes	617	\$2,229,899	\$3,614	\$2,056	145.4 [s]	120.3
6 Malignant Neoplasm of the Breast	143	\$1,740,563	\$12,172	\$14,641	33.7 [s]	24.1
7 Malignant Pulmonary Neoplasm	37	\$1,486,469	\$40,175	\$34,018	8.7 [s]	4.8
8 Neoplastic Disease of Blood and Lymphatic System except Leukemia	242	\$1,399,730	\$5,784	\$6,391	57.0 [s]	27.4
9 Congestive Heart Failure	204	\$1,319,443	\$6,468	\$4,423	48.1	21.0
10 Emphysema/Chronic Bronchitis	202	\$1,291,727	\$6,395	\$2,724	47.6	29.7

1. Any bar marked with / has been truncated.
2. [s] indicates a significant difference from benchmark.

- ◆ The top 10 episode treatment groups (ETGs) drove 36% of combined medical and pharmacy costs—43% of inpatient claims costs, 31% of outpatient claims costs, and 40% of pharmacy claims costs.
- ◆ The rate of routine care was 11% less than the benchmark.
- ◆ Joint degeneration was Boston’s highest cost-ranked ETG. The prevalence of joint degeneration, which includes osteoarthritis, joint replacements and back problems, was 21% higher than the benchmark. This condition was responsible for 9.0% of Boston’s claims. One high cost claimant, representing \$2.59 PMPM in claims, had a primary ETG of joint degeneration. Lack of physical fitness is a risk factor for joint degeneration.
- ◆ The prevalence of coronary artery disease (CAD) was 40% higher than the benchmark and was responsible for 4.8% of claims. Three high cost claimants, representing \$12.51 PMPM in claims, had a primary ETG of CAD.
- ◆ While ‘congestive heart failure’ and ‘emphysema/chronic bronchitis’ are not usually among the top cost-ranked ETGs, high cost claimants drove these ETGs into the top 10. A full listing of high cost claimants is located at the end of this report.

